论文部分内容阅读
目的观察阿托伐他汀联合曲美他嗪治疗冠状动脉粥样硬化性心脏病(冠心病)的临床治疗效果。方法将冠心病患者68例随机分为他汀组和曲美+他汀组各34例。他汀组给予阿托伐他汀治疗,曲美+他汀组给予阿托伐他汀联合曲美他嗪治疗。比较2组患者临床疗效,检测2组干预前后患者低密度脂蛋白胆固醇、左心射血分数及硝酸甘油用量,观察2组不良反应发生情况。结果曲美+他汀组总有效率为94.12%高于他汀组的79.41%,差异有统计学意义(χ2=8.534,P<0.05)。干预前2组低密度脂蛋白胆固醇、左心射血分数及硝酸甘油用量比较差异均无统计学意义(P>0.05);干预后2组低密度脂蛋白胆固醇及硝酸甘油用量均低于治疗前,左心射血分数高于治疗前,且曲美+他汀组变化幅度大于他汀组,差异均有统计学意义(P<0.05)。2组均无严重不良反应发生。结论阿托伐他汀联合曲美他嗪治疗冠心病效果确切,可有效改善患者血脂和心功能,减少硝酸甘油用量,作用安全可靠,值得推广。
Objective To observe the clinical effect of atorvastatin combined with trimetazidine on coronary atherosclerotic heart disease (CHD). Methods 68 patients with coronary heart disease were randomly divided into statin group and trimetazidine group 34 cases. Atorvastatin was given in the statin group and atorvastatin combined with trimetazidine in the trimebutine + statin group. The clinical efficacy of the two groups were compared. The levels of low density lipoprotein cholesterol, left ventricular ejection fraction and nitroglycerin were measured in two groups before and after intervention. The occurrence of adverse reactions in two groups were observed. Results The total effective rate was 94.12% in the trimetazidine group and 79.41% in the statin group, the difference was statistically significant (χ2 = 8.534, P <0.05). There was no significant difference in LDL cholesterol, left ventricular ejection fraction and nitroglycerin level before intervention (P> 0.05). After intervention, the levels of LDL cholesterol and nitroglycerin were both lower than those before treatment , Left heart ejection fraction higher than before treatment, and trimetazidine + statin group than the statin group, the difference was statistically significant (P <0.05). No serious adverse reactions occurred in both groups. Conclusion Atorvastatin combined with trimetazidine treatment of coronary heart disease is exact, can effectively improve the patient’s blood lipids and cardiac function, reduce the amount of nitroglycerin, the role of safe and reliable, it is worth promoting.